IO Biotech raises EUR 11M in series A

Immuno-oncology play IO Biotech ApS (Copenhagen, Denmark) raised EUR 11 million ($12 million) in a series A round from new investor Lundbeckfond Emerge and existing investor Novo A/S (Hellerup, Denmark). Lundbeckfond Emerge is the early stage investment unit of Lundbeckfonden.

IO Biotech spun out from the Center for Cancer Immune Therapy at the University of Copenhagen Herlev Hospital and is developing therapeutic vaccines targeting immune checkpoints for cancer. ...